Trial Profile
Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; KIF20A-VEGFR1 peptide vaccine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 01 Feb 2013 New trial record